IP & Drug Development

Our Approach to Drug Discovery

Our research strategy hinges on identifying and developing novel psychedelic and non-psychedelic molecules for medical use. We use molecules found in nature as building blocks to produce improved second-generation drugs, leveraging artificial intelligence and machine learning (AI/ML) to discover drug enhancements cost effectively and efficiently. This portfolio of new drugs represents major improvements to existing natural and synthetics products, such as enhanced safety, efficacy, stability, dosing and reduced side effects.

Using Research to Understand the Power of Psychedelics

Using Research to Understand the Power of Psychedelics

The goal of creating these improved, second-generation compounds is to enable safer, more effective treatments for patients, along with improved dosage management and drug behavior for clinicians. To create these enhanced molecules, we study the large number of psychedelics reported in the literature, as well as anecdotal reports, to gain an understanding of how these drugs have been used therapeutically, and more importantly, what their shortcomings are.

Breaking Down Psychedelics for Their Best Use

Breaking Down Psychedelics for Their Best Use

A thorough analysis of each drug on a molecular level allows us to determine which features are responsible for undesirable effects and shortcomings. This information is then used to design new second-generation molecules with improved performance, which allows better management in the clinicians’ hands.

Evolving Nature to Its Most Powerful Being

Evolving Nature to Its Most Powerful Being

The current generation of psychedelic natural products evolved in nature, making them most equipped to deal with the organism’s natural environment. Although these molecules have been found remarkably useful for therapeutic use, they are not naturally made for a clinical setting. Therefore, there is an immense demand for these next-generation drugs that will be more responsive to the needs of patients and physicians.